Spectral MD Holdings Full Year 2022 Earnings: US$0.021 loss per share (vs US$0.054 loss in FY 2021)

Simply Wall St

March 01, 2023

Spectral MD Holdings (LON:SMD) Full Year 2022 Results

Key Financial Results

Revenue: US$25.4m (up 67% from FY 2021).
Net loss: US$2.91m (loss narrowed by 46% from FY 2021).
US$0.021 loss per share (improved from US$0.054 loss in FY 2021).

earnings-and-revenue-growth — AIM:SMD Earnings and Revenue Growth March 1st 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Spectral MD Holdings Earnings Insights

Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in the United Kingdom.

Performance of the British Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Spectral MD Holdings that we have uncovered.

If you're looking to trade Spectral MD Holdings, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.